Nivolumab
NCT03718767
National Cancer Institute · Phase 2 · Active, not recruiting · Enrollment 62
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
Nivolumab
National Cancer Institute · Phase 2 · Active, not recruiting · Enrollment 62
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.